BioengineeringCell ReportsPeer-reviewed
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations
F. Bertoglio, V. Fühner, M. Ruschig…·M. Hust
The paper describes the selection of a SARS-CoV-2 neutralizing antibody from COVID-19 patients using phage display, showing it binds the ACE2-RBD interface and remains effective against emerging RBD mutations.
DOI 10.1016/j.celrep.2021.109433